Research Impact

h-index

N/A

Research impact score

Publications

Total publications

Trial Results

Published trial results

Citations

Total citations

Drug Portfolio

DRUG(2)

MIXED(1)

Anlotinib Plus Docetaxel

1 trial

phase_2

first-affiliated-hospital-of-guangxi-medical-university

Docetaxel

1 trial

phase_2

first-affiliated-hospital-of-guangxi-medical-university

Sequential and maintenance icotinib

1 trial

phase_4

betta-pharmaceuticals-co-ltd

3 unique interventions2 categories

Analytics

Trial Phases

Phase 21

Phase 41

Trial Status

Other2

Role Distribution

Principal Investigator2

PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT02194556Phase 4Unknown

Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC

AdenocarcinomaEGFR Positive Non-small Cell Lung Cancer

Principalinvestigator

NCT03654027Phase 2Unknown

Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC

Non-small Cell Lung Cancer

Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections

Network Legend

KOL

Current Investigator

High-influence Collaborator

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Adenocarcinoma1 EGFR Positive Non-small Cell Lung Cancer1 Carcinoma, Non-Small-Cell Lung1

Affiliations

First Affiliated Hospital of Guangxi Medical University

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Steven A Rosenberg, M.D.

National Cancer Institute (NCI)

32 trials

Shared therapeutic areas:

Carcinoma, Non-Small-Cell LungAdenocarcinoma

Similarity Score20%

Arun Rajan, M.D.

National Cancer Institute (NCI)

17 trials

Shared therapeutic areas:

Carcinoma, Non-Small-Cell LungAdenocarcinoma

Similarity Score20%

James L Gulley, M.D.

National Cancer Institute (NCI)

18 trials

Shared therapeutic areas:

AdenocarcinomaCarcinoma, Non-Small-Cell Lung

Similarity Score20%

Ciro Gallo, M.D., Ph.D.

University of Campania Luigi Vanvitelli

8 trials

Shared therapeutic areas:

Carcinoma, Non-Small-Cell Lung

Similarity Score10%

Dong-Xin Wang, MD, PhD

Peking University First Hospital

74 trials

Shared therapeutic areas:

Carcinoma, Non-Small-Cell Lung

Similarity Score10%

Toshimitsu Tokimoto

Astrazeneca KK

16 trials

Shared therapeutic areas:

Carcinoma, Non-Small-Cell Lung

Similarity Score10%

Zhaohui Zhu, MD

Peking Union Medical College Hospital

19 trials

Shared therapeutic areas:

Carcinoma, Non-Small-Cell Lung

Similarity Score10%

Zhengfei Zhu, MD

Fudan University

8 trials

Shared therapeutic areas:

Carcinoma, Non-Small-Cell Lung

Similarity Score10%

You Lu, MD

West China Hospital

18 trials

Shared therapeutic areas:

Carcinoma, Non-Small-Cell Lung

Similarity Score10%

Urielle Desalbres

Assistance Publique Hôpitaux de Marseille

71 trials

Shared therapeutic areas:

Carcinoma, Non-Small-Cell Lung

Similarity Score10%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT02194556Phase 4PrincipalInvestigator

Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC

AdenocarcinomaEGFR Positive Non-small Cell Lung Cancer

Unknown

NCT03654027Phase 2PrincipalInvestigator

Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC

Non-small Cell Lung Cancer

Unknown

All 2 trials loaded